AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CHAI | 0.19 | N/A | +0.70% |
| Core AI Holdings Inc | |||
| HAWX | 44.21 | 0.06 | +0.14% |
| iShares Currency Hedged MSCI ACWI ex U.S. ETF (HAWX) | |||
| ARMW | 29.18 | N/A | -0.02% |
| Roundhill ARM WeeklyPay ETF | |||
| JFLX | 49.10 | -0.06 | -0.13% |
| JPMorgan Flexible Debt ETF (JFLX) | |||
| ERH | 10.59 | -0.05 | -0.42% |
| Allspring Utilities and High Income Fund | |||
A.I.dvisor indicates that over the last year, ATRC has been loosely correlated with CERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRC jumps, then CERS could also see price increases.
| Ticker / NAME | Correlation To ATRC | 1D Price Change % | ||
|---|---|---|---|---|
| ATRC | 100% | -0.56% | ||
| CERS - ATRC | 42% Loosely correlated | +0.87% | ||
| SIBN - ATRC | 41% Loosely correlated | -0.37% | ||
| IRMD - ATRC | 38% Loosely correlated | -2.08% | ||
| TMCI - ATRC | 37% Loosely correlated | -0.23% | ||
| MXCT - ATRC | 37% Loosely correlated | -2.10% | ||
More | ||||
| Ticker / NAME | Correlation To ATRC | 1D Price Change % |
|---|---|---|
| ATRC | 100% | -0.56% |
| Pharmaceuticals: Other industry (49 stocks) | 48% Loosely correlated | -0.17% |
| Pharmaceuticals industry (153 stocks) | 10% Poorly correlated | -1.40% |
a manufacturer of surgical and medical instruments
Industry PharmaceuticalsOther
The Moving Average Convergence Divergence (MACD) for ATRC turned positive on October 23, 2026. Looking at past instances where ATRC's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ATRC as a result. In 62 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
Following a +1.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATRC advanced for three days, in 215 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ATRC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 157 of 222 cases where ATRC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
The 10-day RSI Indicator for ATRC moved out of overbought territory on September 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 23 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATRC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.808) is normal, around the industry mean (4.989). ATRC's P/E Ratio (268.045) is considerably higher than the industry average of (37.210). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.869) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.